SCHEMBL3658360

SCHEMBL3658360

CCCC1(c2ccccc2)NC(=O)N(CC(=O)c2ccc(NC(=O)Cc3c(C)noc3C)cc2)C1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.57
KMT2A Q03164 3/20 0.51
MEN1 O00255 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
MAPT P10636 2/20 0.46
ALDH1A1 P00352 2/20 0.46
HTT P42858 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
GAA P10253 1/20 0.46
TSHR P16473 1/20 0.46
USP2 O75604 1/20 0.44
CRHBP P24387 1/20 0.44
CRHR2 Q13324 1/20 0.44
KEAP1 Q14145 1/20 0.44
NFE2L2 Q16236 1/20 0.44
HPGD P15428 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
POLB P06746 1/20 0.41
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3658740 0.88 MEN1 (0.53) LMNAKMT2AMEN1HTTTSHR
SCHEMBL3656474 0.85 TSHR (0.55) LMNAKMT2AMEN1ALDH1A1HTT
SCHEMBL3655230 0.82 KMT2A (0.53) LMNAKMT2AMEN1HDAC6MAPT
SCHEMBL3660786 0.81 KMT2A (0.57) LMNAKMT2AMEN1HDAC6MAPT
SCHEMBL2984383 0.81 TAS2R8 (0.42) LMNA
SCHEMBL3663347 0.81 KMT2A (0.58) LMNAKMT2AMEN1HDAC6MAPT
SCHEMBL3664126 0.79 KMT2A (0.52) LMNAKMT2AMEN1MAPTALDH1A1
SCHEMBL3662782 0.79 KMT2A (0.56) LMNAKMT2AMEN1HDAC6MAPT
SCHEMBL4121157 0.78 KMT2A (0.55) LMNAKMT2AMEN1HDAC6MAPT
SCHEMBL3660936 0.77 KMT2A (0.60) LMNAKMT2AMEN1HDAC6MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2212314-A1 IMIDAZOLIDINE-2,4-DIONE (HYDANTOIN) DERIVATIVES USEFUL AS NPY Y2 RECEPTOR MODULATORS Novartis AG (CH) 2010-08-04 EP disclosed
WO-2009050200-A1 IMIDAZOLIDINE-2,4-DIONE (HYDANTOIN) DERIVATIVES USEFUL AS NPY Y2 RECEPTOR MODULATORS NOVARTIS AG (CH) 2009-04-23 WO disclosed
US-20090099243-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099243-A1 ORGANIC COMPOUNDS SLCO4C1, SLCO1B1, SLCO1B3 LMNA 2430/4885KMT2A 2020/4885MEN1 155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.